![]() Interestingly, sasanlimab was also included in that deal: Pfizer says the molecule had been originated in house, but the two companies agreed to work together on it, before Pfizer regained rights in December 2018, according to US SEC filings. The deidentified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does. Data may be requested from Pfizer trials 24 months after study completion. About NiKang Therapeutics.Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. ![]() ![]() ![]() Once an appropriate dose is identified, combination studies including NKT2152 and Pfizer's palbociclib and sasanlimab will commence. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |